<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Histopathology, genetics, and molecular groups of medulloblastoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Histopathology, genetics, and molecular groups of medulloblastoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Histopathology, genetics, and molecular groups of medulloblastoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason Fangusaro, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amar Gajjar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Medulloblastomas are the most common malignant brain tumor of childhood and occur exclusively in the cerebellum. Histologically, they are highly cellular tumors with dark staining, round or oval nuclei. On a molecular level, medulloblastomas are heterogeneous and can be divided into four distinct groups with divergent tumor cell histology, genetics, clinical behavior, and patient outcomes.</p><p>The histopathology and molecular pathogenesis of medulloblastoma will be reviewed here. The clinical presentation, diagnosis, and treatment of medulloblastoma in children and adults, prognosis, and the delayed complications in survivors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5219.html" rel="external">"Clinical presentation, diagnosis, and risk stratification of medulloblastoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>At surgery, medulloblastomas are soft, friable tumors, often with necrosis. They are highly cellular tumors with abundant dark staining, round or oval nuclei, and little cytoplasmic differentiation. The spectrum of histopathologic appearance ranges from tumors with extensive nodularity to those with large cell/anaplastic (LCA) features. The clinical outcome appears to be worse with increasing grade and extent of anaplasia [<a href="#rid1">1</a>]. Mitoses are often abundant, and neuroblastic Homer Wright rosettes can be found in up to 40 percent of cases [<a href="#rid2">2,3</a>].</p><p>Immunohistochemical studies most often demonstrate the expression of the neuronal markers synaptophysin and neuron-specific enolase. Nestin, a marker of primitive neuroepithelial cells, consistent with their presumed origin from neuronal progenitors in the cerebellum, is also expressed [<a href="#rid4">4</a>]. Some medulloblastoma subtypes express markers specific for cerebellar granule cells [<a href="#rid5">5,6</a>], supporting the conclusion that they arise most often by oncogenic transformation of cerebellar granule cell progenitors; others express markers suggesting that they arise from multipotential progenitor cells from earlier stages of neural development. Nuclear beta-catenin staining is present in most Wingless-related integration site (Wnt) pathway tumors, and p53 immunostaining can be performed to identify tumors with tumor protein p53 (<em>TP53</em>) mutations. (See <a class="local">'Molecular groups'</a> below.)</p><p>Several histologic variants of medulloblastoma have been described, including classic, desmoplastic/nodular, large cell, and anaplastic  (<a class="graphic graphic_figure graphicRef88305" href="/z/d/graphic/88305.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef109467" href="/z/d/graphic/109467.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]. The desmoplastic variant has abundant collagen and reticulin in the interstitial spaces as well as reticulin-free "pale islands" [<a href="#rid3">3</a>]. This variant is associated with mutations in the patched-1 (<em>PTCH1</em>) gene on chromosome 9 and may have a better prognosis [<a href="#rid8">8</a>]. A second variant, the LCA medulloblastoma, is characterized by cerebrospinal fluid dissemination and a more aggressive clinical course [<a href="#rid9">9</a>]. The LCA variant is most commonly associated with the group 3 molecular subtype in children and with group 4 tumors in adults. (See <a class="local">'Group 3'</a> below and <a class="local">'Group 4'</a> below.)</p><p>The prognostic implications of these histopathologic variants are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5219.html" rel="external">"Clinical presentation, diagnosis, and risk stratification of medulloblastoma", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">GENETIC PREDISPOSITION</span><span class="headingEndMark"> — </span>Approximately 5 to 6 percent of children with medulloblastoma have germline mutations in specific genes that predispose to the development of medulloblastoma and other cancers  (<a class="graphic graphic_table graphicRef118357" href="/z/d/graphic/118357.html" rel="external">table 2</a>) [<a href="#rid10">10-12</a>]. The likelihood of a cancer predisposition syndrome varies by molecular group and is highest in patients with sonic hedgehog (SHH) pathway tumors [<a href="#rid12">12</a>]. An understanding of the molecular pathways involved in these genetic syndromes has provided insights into the pathogenesis of sporadic medulloblastomas as well.</p><p class="headingAnchor" id="H4480307"><span class="h2">Nevoid basal cell carcinoma syndrome (<i>PTCH1</i>, <i>SUFU</i>)</span><span class="headingEndMark"> — </span>Nevoid basal cell carcinoma syndrome (NBCCS; also called Gorlin syndrome) is the most common genetic syndrome associated with medulloblastoma. It is an autosomal dominant disease due to germline mutations in the <em>PTCH1</em> gene on chromosome 9, a key component in the SHH pathway. Less commonly, NBCCS is due to germline mutations in the suppressor of fused (<em>SUFU</em>) gene [<a href="#rid13">13,14</a>]. The mechanism through which <em>PTCH1</em> mutations lead to overactivation of the SHH pathway in NBCCS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)", section on 'Pathogenesis'</a>.)</p><p>During normal cerebellar development, SHH is produced by Purkinje neurons and stimulates growth and migration of granule neuron precursor cells. Overactive SHH signaling plays a key role in the pathogenesis of a subset of sporadic medulloblastomas as well as those associated with NBCCS. The first sporadic mouse model of medulloblastoma was created by germline deletion of one <em>PTCH1</em> allele [<a href="#rid15">15</a>]. (See <a class="local">'SHH pathway'</a> below.)</p><p>Medulloblastoma develops in 3 to 5 percent of patients with NBCCS, typically by the age of three, and may be the earliest overt manifestation of the syndrome [<a href="#rid16">16</a>]. Importantly, <em>SUFU </em>mutation-associated NBCCS appears to be associated with a much higher risk of medulloblastoma than that of <em>PTCH1</em>-associated NBCCS [<a href="#rid13">13,14</a>]. Tumors often show desmoplastic histologic features. Other tumors associated with NBCCS include multiple basal cell cancers and ovarian fibromas. The clinical manifestations of NBCCS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"</a>.)</p><p class="headingAnchor" id="H4480314"><span class="h2">Familial adenomatous polyposis (<i>APC</i>)</span><span class="headingEndMark"> — </span>Familial adenomatous polyposis (FAP) is an autosomal dominant condition caused by inactivating mutations in the adenomatous polyposis coli (<em>APC</em>) gene on chromosome 5. A germline mutation in one <em>APC</em> allele plus a "second hit" deletion of the other allele results in loss of all functional APC protein and a high propensity for colonic polyp formation. The genetics of FAP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">"Clinical manifestations and diagnosis of familial adenomatous polyposis", section on 'Genetics'</a>.)</p><p>APC is part of a protein complex in the Wingless-related integration site (Wnt) signaling pathway, which is a network of proteins that controls cell proliferation and differentiation during development and healing. Loss of APC, as occurs in FAP, ultimately leads to excessive intranuclear accumulation of beta-catenin, an intracellular protein involved in the pathogenesis of medulloblastoma. Deregulation of the Wnt pathway by somatic mutations in the beta-catenin gene, <em>CTNNB1</em>, is also recognized in a subset of sporadic medulloblastomas. <em>CTNNB1</em> mutations appear to be mutually exclusive with germline <em>APC</em> mutations. (See <a class="local">'Wnt pathway'</a> below.)</p><p>Medulloblastoma develops in less than 1 percent of patients with FAP, but the risk may not be uniform across all families [<a href="#rid17">17,18</a>]. It appears to be highest in those with mutations in segment 2 of the <em>APC</em> gene [<a href="#rid19">19</a>]. If this observation is confirmed, patients with mutations in this portion of the <em>APC</em> gene might be candidates for earlier genetic counseling and surveillance.</p><p class="headingAnchor" id="H2825844162"><span class="h2">Li-Fraumeni syndrome (<i>TP53</i>)</span><span class="headingEndMark"> — </span>Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome associated with abnormalities in the <em>TP53</em> gene on chromosome 17p. The spectrum of malignancies associated with LFS includes osteosarcoma, soft tissue sarcoma, breast cancer, adrenocortical carcinoma, and a range of brain tumors, including high-grade gliomas, medulloblastoma, and choroid plexus carcinoma. (See  <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a>.)</p><p>Germline <em>TP53</em> mutations are rarely identified in unselected patients with medulloblastoma but make up approximately 8 percent of SHH pathway tumors [<a href="#rid12">12</a>]. When present, they are usually associated with somatic inactivation of the wildtype <em>TP53</em> allele, complex genomic rearrangements, and a poor prognosis compared with other SHH pathway tumors [<a href="#rid20">20-22</a>]. (See <a class="local">'SHH pathway'</a> below.)</p><p>In a multinational retrospective study of 47 children with LFS-associated medulloblastoma (all SHH pathway tumors), the median age at diagnosis was 9.1 years, 66 percent of patients were male, and the majority (77 percent) presented with stage M0 disease [<a href="#rid21">21</a>]. Two- and five-year progression-free survival were 36 and 20 percent, respectively, and two- and five-year overall survival were 53 and 23 percent. Nearly all patients received both radiation therapy (91 percent) and chemotherapy (89 percent). Approximately three-quarters of deaths were due to recurrent/progressive medulloblastoma, and the remaining deaths were due to a different subsequent malignancy.</p><p class="headingAnchor" id="H1687017393"><span class="h2">Other germline mutations (<i>BRCA2</i>, <i>PALB2</i>, <i>GPR161</i>)</span><span class="headingEndMark"> — </span>Germline mutations in several genes have been identified in patients with medulloblastoma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRCA2</em></strong> – Biallelic (homozygous or compound heterozygous) mutations in the breast cancer type 2 susceptibility (<em>BRCA2</em>, also known as <em>FANCD1</em>) gene are a cause of Fanconi anemia, and heterozygous <em>BRCA2</em> mutations are a well-established cause of familial breast and ovarian cancer. (See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a>.)</p><p></p><p class="bulletIndent1">Both types of pathogenic germline <em>BRCA2</em> abnormalities (ie, heterozygous mutations and biallelic mutations) have been identified in patients with medulloblastoma [<a href="#rid12">12,23</a>]. In a cohort of over 1000 patients with medulloblastoma, <em>BRCA2</em> mutations were identified in 11 patients (1 percent) [<a href="#rid12">12</a>]. The median age at diagnosis was 5.7 years. Four of 11 patients had compound heterozygosity; all of these had SHH pathway tumors and clinical features of Fanconi anemia. Tumors associated with heterozygous <em>BRCA2 </em>mutations were distributed across multiple molecular groups (SHH, group 3, and group 4).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>PALB2</em></strong> – Rare pathogenic germline mutations in the partner and localizer of <em>BRCA2</em> (<em>PALB2</em>) gene have been described in patients with medulloblastoma across multiple molecular groups (SHH, group 3, and group 4) [<a href="#rid12">12</a>]. All reported cases associated with medulloblastoma have been heterozygous mutations, which separately have been associated with hereditary predisposition to adult-onset breast and ovarian cancer. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'PALB2'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>GPR161</em></strong> – A novel brain tumor predisposition syndrome caused by mutations in the SHH regulator G protein-coupled receptor 161 (<em>GPR161</em>) gene has been described [<a href="#rid24">24</a>]. Such mutations may be present in approximately 5 percent of patients with infantile SHH medulloblastoma. Mutations are associated with loss of heterozygosity at chromosome 1q, leading to biallelic inactivation of <em>GPR161</em>. SHH medulloblastoma in infancy (median age, 1.5 years) is the defining tumor based on the small number of cases identified to date. Further studies are needed to define the full phenotypic spectrum, which may include increased risk of colorectal cancer and ovarian cancer in adulthood.</p><p></p><p>Medulloblastomas associated with <em>BRCA2</em> or <em>PALB2 </em>mutations have an increased prevalence of homologous recombination repair deficiency (HRD). An HRD-like mutation spectrum has also been observed in medulloblastomas associated with heterozygous germline mutations in ataxia telangiectasia mutated (<em>ATM</em>), Fanconi anemia complementation group A (<em>FANCA</em>), and <em>FANCQ </em>[<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1627576661"><span class="h2">Genetic counseling and testing</span><span class="headingEndMark"> — </span>The identification of a cancer predisposition gene has important implications for the patient and family members with regard to future risk, screening, and reproductive decision-making. Although a large majority of medulloblastomas are sporadic, the likelihood of a cancer predisposition mutation varies by molecular group and may be as high as 20 percent for SHH pathway tumors. Importantly, only 40 to 45 percent of patients with medulloblastoma related to a germline cancer predisposition gene have a family history of cancer or clinical signs of a predisposing syndrome, suggesting that genetic predisposition syndrome testing must be considered even without a family history [<a href="#rid12">12</a>].</p><p>Proposed guidelines  (<a class="graphic graphic_table graphicRef118357" href="/z/d/graphic/118357.html" rel="external">table 2</a>) recommend that genetic testing and counseling be offered to all patients with SHH pathway tumors, all patients with Wnt pathway tumors that are not known to have a somatic <em>CTNNB1</em> mutation, and selected patients with group 3 and 4 tumors (eg, tumors with an HRD molecular signature and patients with a family history of BRCA-associated tumors) [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H4480322"><span class="h1">MOLECULAR GROUPS</span><span class="headingEndMark"> — </span>Gene expression profiling using tumor tissue microarrays is an approach to molecular classification of medulloblastoma. Several large studies using medulloblastoma samples pooled from multiple centers have attempted to subclassify medulloblastoma based on genome-wide DNA copy number, mRNA expression profiles, and somatic copy number aberrations [<a href="#rid25">25-30</a>]. Several different classifications have been generated; the most widely accepted separates medulloblastoma into four distinct molecular groups: sonic hedgehog (SHH), Wingless-related integration site (Wnt), group 3, and group 4 [<a href="#rid31">31</a>]. Somatic mutations identified through whole genome or whole exome sequencing also appear to segregate into these groups [<a href="#rid32">32-34</a>].</p><p>These groups have divergent tumor cell histology, genetics, clinical behavior, and patient outcomes  (<a class="graphic graphic_figure graphicRef87770" href="/z/d/graphic/87770.html" rel="external">figure 2</a>) and are recognized genetically defined diagnoses in the World Health Organization (WHO) classification system  (<a class="graphic graphic_table graphicRef109467" href="/z/d/graphic/109467.html" rel="external">table 1</a>) [<a href="#rid25">25-27,32,35</a>]. Molecular groups are playing an increasingly important role in the design of clinical trials and development of new treatment paradigms, including targeted therapies [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H5"><span class="h2">SHH pathway</span><span class="headingEndMark"> — </span>The granule cell progenitors can be stimulated to proliferate by the cerebellar Purkinje cells in a process that is mediated by SHH protein. Overactive signaling by SHH appears to have a proliferative effect on these cells and thus contributes to the pathogenesis of medulloblastoma in several ways:</p><p class="bulletIndent1"><span class="glyph">●</span>SHH binds to its receptor, PTCH1. In the absence of binding to SHH, PTCH1 normally interacts with Smoothened (SMO), blocking the activation of a number of downstream transcription pathways. Overactive signaling by SHH prevents the inhibition of these pathways by PTCH1  (<a class="graphic graphic_figure graphicRef69105" href="/z/d/graphic/69105.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SHH appears to upregulate the <em>MYCN</em> gene. N-myc, the protein product of <em>MYCN,</em> has multiple effects in the cell cycle, and degradation of N-myc appears necessary for the granule cell progenitors to exit the cell cycle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some cases, SHH signaling is enhanced by loss of function of a tumor suppressor gene. One example is <em>GNAS</em>, which encodes the G protein alpha subunit<sub> </sub>[<a href="#rid37">37</a>]. The alpha subunit is enriched in granule neuron precursors in the cerebellum and suppresses SHH signaling through cyclic adenosine monophosphate (cAMP)-dependent pathway regulation, among other functions. The importance of this pathway is further supported by the finding of medulloblastoma in an infant with a homozygous nonsense mutation within the <em>GNAS</em> coding region [<a href="#rid38">38</a>]. Another example is the tumor suppressor gene <em>GPR161</em>, which acts as a negative regulator of SHH signaling [<a href="#rid24">24</a>].</p><p></p><p>Activation of the SHH pathway can occur in the absence of germline or somatic mutations to <em>PTCH1</em> in patients with medulloblastoma. These include truncating mutations of <em>PTCH2</em>, a homologue of <em>PTCH1</em> that is localized to the short arm of chromosome 1 [<a href="#rid39">39</a>]; both somatic and germline mutations in the <em>SUFU</em>, another gene involved in the SHH pathway that is localized to chromosome 10q [<a href="#rid40">40</a>]; and mutations in <em>GLI3</em>, a downstream component of the SHH pathway, located on chromosome 7p [<a href="#rid41">41</a>]. A subset of these tumors have mutations in isocitrate dehydrogenase type 1 (<em>IDH1</em>) and exhibit a hypermethylation phenotype [<a href="#rid42">42</a>]. Approximately 20 percent harbor mutations that target histone acetyltransferase (HAT) complexes.</p><p>Alterations in the SHH pathway are present in approximately 30 percent of medulloblastomas. As in nevoid basal cell carcinoma syndrome (NBCCS) associated tumors, these medulloblastomas are often desmoplastic [<a href="#rid40">40</a>]. (See <a class="local">'Nevoid basal cell carcinoma syndrome (PTCH1, SUFU)'</a> above.)</p><p>Somatic <em>TP53 </em>mutations have been identified in 10 to 20 percent of SHH tumors and are important biologically and prognostically [<a href="#rid12">12,20</a>].<em> TP53</em>-mutant SHH tumors often harbor high-level <em>MYC</em> amplification and chromosomal instability [<a href="#rid20">20,43</a>]. Unlike <em>TP53</em> wildtype SHH tumors, which are overrepresented in infants and adults with medulloblastoma [<a href="#rid26">26</a>], <em>TP53-</em>mutant SHH tumors have a peak incidence in adolescence [<a href="#rid20">20</a>]. Patients with <em>TP53</em>-mutant SHH tumors have a much worse survival outcome compared with those with <em>TP53</em> wildtype SHH tumors, with a five-year overall survival of approximately 40 percent. A significant number harbor germline mutations in <em>TP53</em>, indicative of the Li-Fraumeni cancer predisposition syndrome. (See  <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a>.)</p><p>SHH tumors with wildtype <em>TP53</em> are most common in infants and adults with medulloblastoma [<a href="#rid26">26</a>]. Patients with these tumors have an intermediate prognosis, with overall survival rates of approximately 80 percent.</p><p>Antagonists of the SHH pathway are an active area of investigation, although early enthusiasm has been dampened by acquired resistance and early relapse with monotherapy [<a href="#rid44">44,45</a>]. In addition, SHH antagonist therapy causes bony abnormalities in developing children and must be given with caution to patients who have incomplete skeletal growth or who are skeletally immature.</p><p class="headingAnchor" id="H6"><span class="h2">Wnt pathway</span><span class="headingEndMark"> — </span>The Wnt protein binds to its receptor, Frizzled, and this interaction destabilizes a multiprotein complex that includes the APC protein. This in turn initiates a sequence of events that can activate various transcription factors, which are important in the pathogenesis of medulloblastoma. Loss of chromosome 6 and somatic mutations of <em>CTNNB1</em> that promote stabilization and nuclear localization of beta-catenin are present in approximately 85 to 90 percent of Wnt pathway tumors [<a href="#rid42">42</a>]. <em>TP53</em> mutations are present in approximately 15 percent of Wnt pathway tumors [<a href="#rid12">12,20</a>]. Most tumors that lack a somatic <em>CTNNB1</em> mutation are associated with germline <em>APC</em> mutations [<a href="#rid12">12</a>].</p><p>Wnt pathway tumors make up approximately 10 percent of all medulloblastomas, making it the least common group [<a href="#rid31">31</a>]. Approximately 6 to 8 percent of patients with Wnt pathway tumors harbor a germline <em>APC</em> mutation as seen in familial adenomatous polyposis (FAP) [<a href="#rid12">12</a>]. (See <a class="local">'Familial adenomatous polyposis (APC)'</a> above.)</p><p>Wnt tumors are seen in children and adults but rarely infants. They metastasize infrequently and, in children, are associated with the most favorable prognosis out of the four groups, with a five-year survival of over 95 percent [<a href="#rid26">26,46</a>]. However, prognosis appears to be worse in adults [<a href="#rid46">46</a>]. (See <a class="local">'Familial adenomatous polyposis (APC)'</a> above.)</p><p class="headingAnchor" id="H4480330"><span class="h2">Group 3</span><span class="headingEndMark"> — </span>High-level amplification of the <em>MYC</em> proto-oncogene is characteristic of group 3 medulloblastomas, and almost all cases exhibit aberrant <em>MYC </em>expression [<a href="#rid25">25,28</a>]. Group 3 tumors are also characterized by high levels of genomic instability. In approximately one-third of group 3 tumors, somatic genomic rearrangements have been described that lead to activation of growth factor independence 1 (<em>GFI1</em>) or <em>GFI1B</em> proto-oncogenes, a process termed "enhancer hijacking" [<a href="#rid42">42,47</a>]. Group 3 is also enriched in alterations in the Notch and transforming growth factor-beta (TGF-beta) signaling pathways as well as hotspot insertions targeting <em>KBTBD4</em> [<a href="#rid42">42</a>].</p><p>Group 3 tumors comprise approximately 25 percent of sporadic medulloblastomas and are seen primarily in children [<a href="#rid31">31,46</a>]. They are enriched for the large cell/anaplastic (LCA) histologic variant and are frequently metastatic at the time of diagnosis. Up to 2 percent of group 3 tumors are associated with germline mutations in a cancer predisposition gene such as the <em>BRCA2</em> gene [<a href="#rid12">12</a>]. (See <a class="local">'Other germline mutations (BRCA2, PALB2, GPR161)'</a> above.)</p><p>Group 3 tumors have the worst prognosis of the four groups, with an increased likelihood of metastatic recurrence [<a href="#rid48">48</a>] and a five-year survival of approximately 50 percent [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H4480338"><span class="h2">Group 4</span><span class="headingEndMark"> — </span>Many group 4 tumors exhibit amplification of the proto-oncogenes <em>MYCN</em> and cyclin-dependent kinase 6 (<em>CDK6</em>). Characteristic cytogenetic abnormalities include isochromosome 17q and loss of one copy of the X chromosome (in females). A small proportion of group 4 tumors have <em>GFI1 </em>or <em>GFI1B</em> activation due to somatic structural variants, as described more commonly in group 3 tumors [<a href="#rid42">42,47</a>]. More commonly, group 4 tumors exhibit structural variants in <em>SNCAIP</em> associated with enhancer hijacking of the <em>PRDM6</em> gene [<a href="#rid42">42</a>]. Hotspot insertions targeting <em>KBTBD4</em> are also common [<a href="#rid42">42</a>].</p><p>Approximately 35 percent of sporadic medulloblastomas fall into this group [<a href="#rid31">31</a>]. Tumors usually exhibit classic histology. There is a strong male predominance (3:1) and a peak incidence in adolescence. Rare patients harbor a germline mutation in <em>BRCA2</em> or the <em>PALB2</em> gene [<a href="#rid12">12</a>]. (See <a class="local">'Other germline mutations (BRCA2, PALB2, GPR161)'</a> above.)</p><p>The prognosis in children is similar to the SHH group, with a 35 to 40 percent rate of metastasis at diagnosis and five-year survival of approximately 75 percent [<a href="#rid31">31</a>]. By contrast, the prognosis of group 4 tumors in adults appears to be significantly worse than that of SHH tumors, with a high incidence of high-risk disease and LCA histology [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H4480625"><span class="h1">CELL OF ORIGIN</span><span class="headingEndMark"> — </span>There is evidence that the cell of origin differs according to molecular group, and putative cells of origin have been identified for each group [<a href="#rid49">49</a>].</p><p>Available data suggest that sonic hedgehog (SHH) medulloblastomas arise from cerebellar granule cell progenitor cells in the upper rhombic lip [<a href="#rid49">49-51</a>]. Wingless-related integration site (Wnt) tumors appear to arise in lower rhombic lip multipotential progenitors of the dorsal brainstem [<a href="#rid49">49,52</a>]. Group 3 and 4 tumors likely arise from cells in the rhombic lip germinal zone, which give rise to glutamatergic neurons including photoreceptor cells and unipolar brush cells of the cerebellum [<a href="#rid49">49,53,54</a>].</p><p>Progression to medulloblastoma is thought to occur when these progenitor cells are subject to continued stimulation or there is a failure of these cells to exit the cell cycle.</p><p class="headingAnchor" id="H7"><span class="h1">GENETIC REGULATION OF METASTASIS</span><span class="headingEndMark"> — </span>Medulloblastomas have a tendency to disseminate throughout the central nervous system early in the course of the disease, and metastatic disease is associated with a poor outcome. Studies of matched primary and recurrent tissue samples show that the four-group molecular signature is retained at the time of recurrence [<a href="#rid48">48</a>]. Group 3 and 4 tumors in particular have a higher likelihood of metastatic recurrence compared with sonic hedgehog (SHH) pathway tumors, which are more likely to recur locally. (See  <a class="medical medical_review" href="/z/d/html/5219.html" rel="external">"Clinical presentation, diagnosis, and risk stratification of medulloblastoma"</a>.)</p><p>In one report of 23 primary medulloblastomas, of which 10 were metastatic and 13 nonmetastatic, the platelet-derived growth factor receptor (PDGFR)-alpha was upregulated and overexpressed in the metastatic tumors and associated with migratory behavior [<a href="#rid55">55</a>]. Cell culture experiments with medulloblastoma cell lines demonstrated that overexpression of PDGFR-alpha increased the phosphorylation and upregulation of downstream Ras/mitogen-activated protein (MAP) kinase signal transduction pathways, while inhibition of these MAP kinases prevented PDGFR-alpha-stimulated migration in a cell culture assay. Further analysis revealed upregulated expression of PDGFR-beta in metastatic medulloblastomas, indicating a role of several PDGFR isoforms in medulloblastoma biology [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Medulloblastomas are highly cellular tumors presumed to arise from neuronal precursors in the cerebellum. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic predisposition</strong> – In approximately 5 to 6 percent of cases, medulloblastomas are associated with an underlying genetic predisposition due to a germline mutation in one of several cancer susceptibility genes  (<a class="graphic graphic_table graphicRef118357" href="/z/d/graphic/118357.html" rel="external">table 2</a>). (See <a class="local">'Genetic predisposition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The nevoid basal cell carcinoma (Gorlin) syndrome (NBCCS) is due to mutations in the patched-1 (<em>PTCH1</em>) or suppressor of fused (<em>SUFU</em>) genes, which are key components in the sonic hedgehog (SHH) pathway. (See <a class="local">'Nevoid basal cell carcinoma syndrome (PTCH1, SUFU)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In familial adenomatosis polyposis (FAP) syndrome, medulloblastomas are seen in conjunction with colonic polyposis. This syndrome is caused by mutations in the adenomatous polyposis coli (<em>APC</em>) gene, which affect the Wingless-related integration site (Wnt) pathway. (See <a class="local">'Familial adenomatous polyposis (APC)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling and testing</strong> – The identification of a cancer predisposition gene has important implications for the patient and family members with regard to future risk, screening, and reproductive decision-making. Although a large majority of medulloblastomas are sporadic, the likelihood of a cancer predisposition mutation varies by molecular group and may be as high as 20 percent for SHH pathway tumors  (<a class="graphic graphic_table graphicRef118357" href="/z/d/graphic/118357.html" rel="external">table 2</a>). (See <a class="local">'Genetic counseling and testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular groups</strong> – Four molecular groups of medulloblastoma have been identified that have divergent tumor cell histology, genetics, clinical behavior, and patient outcomes: SHH, Wnt, group 3, and group 4  (<a class="graphic graphic_table graphicRef109467" href="/z/d/graphic/109467.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef87770" href="/z/d/graphic/87770.html" rel="external">figure 2</a>). (See <a class="local">'Molecular groups'</a> above.)</p><p></p><p class="headingAnchor" id="H2592111687"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Scott L Pomeroy, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002; 94:552.</a></li><li class="breakAll">Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System, Springer-Verlag, Berlin 1993.</li><li><a class="nounderline abstract_t">Katsetos CD, Liu HM, Zacks SI. Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the "pale islands" of human cerebellar medulloblastomas. Hum Pathol 1988; 19:1219.</a></li><li><a class="nounderline abstract_t">McLendon RE, Friedman HS, Fuchs HE, et al. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology 1999; 34:154.</a></li><li><a class="nounderline abstract_t">Kozmik Z, Sure U, Rüedi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A 1995; 92:5709.</a></li><li><a class="nounderline abstract_t">Yokota N, Aruga J, Takai S, et al. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 1996; 56:377.</a></li><li class="breakAll">Giangaspero F, Eberhart CG, Haapasalo H, et al. Medulloblastoma. In: WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2007. p.132.</li><li><a class="nounderline abstract_t">Sure U, Berghorn WJ, Bertalanffy H, et al. Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir (Wien) 1995; 132:59.</a></li><li><a class="nounderline abstract_t">Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001; 95:82.</a></li><li><a class="nounderline abstract_t">Evans G, Burnell L, Campbell R, et al. Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Med Pediatr Oncol 1993; 21:433.</a></li><li><a class="nounderline abstract_t">Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64:959.</a></li><li><a class="nounderline abstract_t">Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018; 19:785.</a></li><li><a class="nounderline abstract_t">Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014; 32:4155.</a></li><li><a class="nounderline abstract_t">Guerrini-Rousseau L, Dufour C, Varlet P, et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro Oncol 2018; 20:1122.</a></li><li><a class="nounderline abstract_t">Goodrich LV, Milenković L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109.</a></li><li><a class="nounderline abstract_t">Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003; 98:618.</a></li><li><a class="nounderline abstract_t">Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332:839.</a></li><li><a class="nounderline abstract_t">Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57:704.</a></li><li><a class="nounderline abstract_t">Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 2007; 109:761.</a></li><li><a class="nounderline abstract_t">Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31:2927.</a></li><li><a class="nounderline abstract_t">Kolodziejczak AS, Guerrini-Rousseau L, Planchon JM, et al. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro Oncol 2023; 25:2273.</a></li><li><a class="nounderline abstract_t">Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010; 28:1345.</a></li><li><a class="nounderline abstract_t">Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003; 95:1548.</a></li><li><a class="nounderline abstract_t">Begemann M, Waszak SM, Robinson GW, et al. Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. J Clin Oncol 2020; 38:43.</a></li><li><a class="nounderline abstract_t">Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408.</a></li><li><a class="nounderline abstract_t">Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473.</a></li><li><a class="nounderline abstract_t">Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012; 488:49.</a></li><li><a class="nounderline abstract_t">Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424.</a></li><li><a class="nounderline abstract_t">Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3:e3088.</a></li><li><a class="nounderline abstract_t">Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24:1924.</a></li><li><a class="nounderline abstract_t">Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12:818.</a></li><li><a class="nounderline abstract_t">Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488:106.</a></li><li><a class="nounderline abstract_t">Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43.</a></li><li><a class="nounderline abstract_t">Jones DT, Jäger N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100.</a></li><li class="breakAll">WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), International Agency for Research on Cancer, 2016.</li><li><a class="nounderline abstract_t">Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014; 32:886.</a></li><li><a class="nounderline abstract_t">He X, Zhang L, Chen Y, et al. The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med 2014; 20:1035.</a></li><li><a class="nounderline abstract_t">Huh JY, Kwon MJ, Seo KY, et al. Novel nonsense GNAS mutation in a 14-month-old boy with plate-like osteoma cutis and medulloblastoma. J Dermatol 2014; 41:319.</a></li><li><a class="nounderline abstract_t">Smyth I, Narang MA, Evans T, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 1999; 8:291.</a></li><li><a class="nounderline abstract_t">Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31:306.</a></li><li><a class="nounderline abstract_t">Erez A, Ilan T, Amariglio N, et al. GLI3 is not mutated commonly in sporadic medulloblastomas. Cancer 2002; 95:28.</a></li><li><a class="nounderline abstract_t">Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature 2017; 547:311.</a></li><li><a class="nounderline abstract_t">Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148:59.</a></li><li><a class="nounderline abstract_t">Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173.</a></li><li><a class="nounderline abstract_t">Metcalfe C, de Sauvage FJ. Hedgehog fights back: Mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71:5057.</a></li><li><a class="nounderline abstract_t">Zhao F, Ohgaki H, Xu L, et al. Molecular subgroups of adult medulloblastoma: A long-term single-institution study. Neuro Oncol 2016; 18:982.</a></li><li><a class="nounderline abstract_t">Northcott PA, Lee C, Zichner T, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014; 511:428.</a></li><li><a class="nounderline abstract_t">Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 2013; 14:1200.</a></li><li><a class="nounderline abstract_t">Hovestadt V, Smith KS, Bihannic L, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature 2019; 572:74.</a></li><li><a class="nounderline abstract_t">Schüller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008; 14:123.</a></li><li><a class="nounderline abstract_t">Grammel D, Warmuth-Metz M, von Bueren AO, et al. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol 2012; 123:601.</a></li><li><a class="nounderline abstract_t">Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468:1095.</a></li><li><a class="nounderline abstract_t">Smith KS, Bihannic L, Gudenas BL, et al. Unified rhombic lip origins of group 3 and group 4 medulloblastoma. Nature 2022; 609:1012.</a></li><li><a class="nounderline abstract_t">Hendrikse LD, Haldipur P, Saulnier O, et al. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature 2022; 609:1021.</a></li><li><a class="nounderline abstract_t">MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29:143.</a></li><li><a class="nounderline abstract_t">Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003; 35:197.</a></li></ol></div><div id="topicVersionRevision">Topic 5218 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11900240" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11900240" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139544" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the "pale islands" of human cerebellar medulloblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064395" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7777574" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Deregulated expression of PAX5 in medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542595" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542595" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7754860" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453402" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515724" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1931625" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753700" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403219" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29186568" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9262482" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Altered neural cell fates and medulloblastoma in mouse patched mutants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12879481" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661930" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The molecular basis of Turcot's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18194984" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Guidelines for the clinical management of familial adenomatous polyposis (FAP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17238184" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835706" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37379234" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142599" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14559878" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31609649" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823417" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Medulloblastoma comprises four distinct molecular variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22358457" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832581" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Subgroup-specific structural variation across 1,000 medulloblastoma genomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098324" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18769486" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567768" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175120" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Medulloblastomics: the end of the beginning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820256" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722829" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Novel mutations target distinct subgroups of medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832583" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dissecting the genomic complexity underlying medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832583" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dissecting the genomic complexity underlying medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24493713" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cytogenetic prognostication within medulloblastoma subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150496" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The G proteinαsubunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24517547" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Novel nonsense GNAS mutation in a 14-month-old boy with plate-like osteoma cutis and medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9931336" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12068298" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mutations in SUFU predispose to medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115313" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : GLI3 is not mutated commonly in sporadic medulloblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28726821" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The whole-genome landscape of medulloblastoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265402" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726761" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21771911" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27106407" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Molecular subgroups of adult medulloblastoma: a long-term single-institution study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25043047" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140199" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31341285" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Resolving medulloblastoma cellular architecture by single-cell genomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691547" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22349907" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150899" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Subtypes of medulloblastoma have distinct developmental origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36131015" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Unified rhombic lip origins of group 3 and group 4 medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36131014" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Failure of human rhombic lip differentiation underlies medulloblastoma formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544480" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14593398" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : PDGFRB is overexpressed in metastatic medulloblastoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
